Difference between revisions of "Part:BBa K274002:Experience"

(User Reviews)
 
(One intermediate revision by the same user not shown)
Line 8: Line 8:
  
 
Judging by the violacein biosynthesis pathways scheme uploaded on the [https://parts.igem.org/Part:BBa_K274002 main page], the results imply that spontaneous transformations of intermediates in the violacein biosynthetic pathway occur frequently, therefore reducing the biosynthetic flow towards violacein and resulting in a lower yield of the latter. Since violacein is a potentially very applicable compound in terms of medicine and other applications (for instance natural purple dyes), it is interesting for industrial production that could be problematic because of the unwanted side products like deoxychromoviridans. That is why [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia] has decided to improve the violacein biosynthetic pathway. Therefore we designed new constructs derived from [[Part:BBa_K274002]]. We designed chimeric ''vio'' enzymes, fused with zinc finger proteins ([[Part:BBa_K323132]] and [[Part:BBa_K323135]]). We showed higher yields of violacein production where biosynthetic enzymes are bound to zinc fingers and through them to DNA scaffold (called DNA program). DNA program was designed in such a way, that it arranges biosynthetic enzymes in a correct order, leading to close proximity which ensures higher yields of biosynthesis and decreases formation of side products. See our project on [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia].
 
Judging by the violacein biosynthesis pathways scheme uploaded on the [https://parts.igem.org/Part:BBa_K274002 main page], the results imply that spontaneous transformations of intermediates in the violacein biosynthetic pathway occur frequently, therefore reducing the biosynthetic flow towards violacein and resulting in a lower yield of the latter. Since violacein is a potentially very applicable compound in terms of medicine and other applications (for instance natural purple dyes), it is interesting for industrial production that could be problematic because of the unwanted side products like deoxychromoviridans. That is why [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia] has decided to improve the violacein biosynthetic pathway. Therefore we designed new constructs derived from [[Part:BBa_K274002]]. We designed chimeric ''vio'' enzymes, fused with zinc finger proteins ([[Part:BBa_K323132]] and [[Part:BBa_K323135]]). We showed higher yields of violacein production where biosynthetic enzymes are bound to zinc fingers and through them to DNA scaffold (called DNA program). DNA program was designed in such a way, that it arranges biosynthetic enzymes in a correct order, leading to close proximity which ensures higher yields of biosynthesis and decreases formation of side products. See our project on [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia].
 +
 +
<html>
 +
 +
<h3>
 +
<b>Experience: UCSF iGEM 2012</b></h3>
 +
The <a href="http://2012.igem.org/Team:UCSF">2012 UCSF iGEM Team </a> team obtained a violacein standard from Sigma-Aldrich,<a href="http://www.sigmaaldrich.com/catalog/product/sigma/v9389?lang=en&region=US">Item:V9389-1MG </a><span>. We used this standard to measure the absorbance of violacein at varying concentrations, obtaining the standard curve shown below. Full wavelength scans were obtained, but as shown by previous iGEM teams (<a href="http://2009.igem.org/Team:Cambridge/Project/Violacein">Cambridge 2009 </a>) the maximum absorbance of violacein is seen at 575nm and is reported here. <br>
 +
 +
<img align="left" style="margin-bottom:8px;margin-right:190px;margin-left:190px; width:555px;height:310px; padding:0;" src="https://dl.dropbox.com/u/24404809/iGEM%202012/igem%202012%20website%20photos/violacein/100212vio_std_cf.jpg"> <br> <p>
 +
 +
 +
<regulartext>
 +
While other teams and papers have reported that extracting pigment from cultures is the best way to perform analysis and quantification, several different solvents have been reported. The 2009 Cambridge iGEM team used acetone to extract, so we tested extraction of violacen from our Strain 3 (which contains the full violacein operon) using acetone as well as methanol and ethanol. <p>
 +
 +
<img align="left" style="margin-bottom:8px;margin-right:190px;margin-left:190px; width:555px;height:310px; padding:0;" src="https://dl.dropbox.com/u/24404809/iGEM%202012/igem%202012%20website%20photos/violacein/100112op_solvents.jpg"> <br> <p>
 +
 +
<regulartext>
 +
Our results show that ethanol was the best solvent to use for extraction and it is much easier to use/less harmful than several of the previously reported solvents. <br>
 +
<p>
 +
 +
</html>
 +
 +
  
  

Latest revision as of 22:22, 3 October 2012


[http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia] has analysed products of this part along with products of Part:BBa_K274004 by thin-layer chromatography and mass spectrometry (for a detailed description of the procedures see the 2010 iGEM team Slovenia [http://2010.igem.org/Team:Slovenia/METHODS_and_PARTS/protocols/bm#TLC wiki]). Unfortunately we had problems with transformation of Part:BBa_K274002 in E.coli, so we constructed our own vio operon from Part:BBa_K274003, Part:BBa_B0034 and a vioC gene, amplified by PCR from Part:BBa_K274004. Transcription of the construct therefore resulted in same proteins as Part:BBa_K274002.

Figure: TLC separation of culture extracts on a silica gel HPTLC plate under white light and UV light.

Results of our experiments show that both of the tested constructs lead to synthesis of three main compounds, namely violacein, deoxyviolacein and deoxychromoviridans (this was confirmed with standards and MS). Part:BBa_K274002 produces a large amount of deoxyviolacein, and smaller amounts of violacein and deoxychromoviridans, while Part:BBa_K274004 results in production of deoxychromoviridans and some deoxyviolacein rather than violacein.

Judging by the violacein biosynthesis pathways scheme uploaded on the main page, the results imply that spontaneous transformations of intermediates in the violacein biosynthetic pathway occur frequently, therefore reducing the biosynthetic flow towards violacein and resulting in a lower yield of the latter. Since violacein is a potentially very applicable compound in terms of medicine and other applications (for instance natural purple dyes), it is interesting for industrial production that could be problematic because of the unwanted side products like deoxychromoviridans. That is why [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia] has decided to improve the violacein biosynthetic pathway. Therefore we designed new constructs derived from Part:BBa_K274002. We designed chimeric vio enzymes, fused with zinc finger proteins (Part:BBa_K323132 and Part:BBa_K323135). We showed higher yields of violacein production where biosynthetic enzymes are bound to zinc fingers and through them to DNA scaffold (called DNA program). DNA program was designed in such a way, that it arranges biosynthetic enzymes in a correct order, leading to close proximity which ensures higher yields of biosynthesis and decreases formation of side products. See our project on [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia].

Experience: UCSF iGEM 2012

The 2012 UCSF iGEM Team team obtained a violacein standard from Sigma-Aldrich,Item:V9389-1MG . We used this standard to measure the absorbance of violacein at varying concentrations, obtaining the standard curve shown below. Full wavelength scans were obtained, but as shown by previous iGEM teams (Cambridge 2009 ) the maximum absorbance of violacein is seen at 575nm and is reported here.

While other teams and papers have reported that extracting pigment from cultures is the best way to perform analysis and quantification, several different solvents have been reported. The 2009 Cambridge iGEM team used acetone to extract, so we tested extraction of violacen from our Strain 3 (which contains the full violacein operon) using acetone as well as methanol and ethanol.


Our results show that ethanol was the best solvent to use for extraction and it is much easier to use/less harmful than several of the previously reported solvents.




Applications of BBa_K274002

The Johns Hopkins 2011 team has taken this part and retooled it for expression in S. cerevisiae. Each gene in the operon will be represented by a separate part for compatibility with eukaryotic expression. We have held off on submission to the Registry due to the presence of illegal sites that we plan to fix with quick-change PCR in the next two weeks.

User Reviews

UNIQacc427a42a0320d9-partinfo-00000001-QINU UNIQacc427a42a0320d9-partinfo-00000002-QINU

Sequence analysis of this part reveals that there is a SpeI site where the XbaI site should be. In addition there is insufficient length between the BioBrick sites (i.e. this is not a standard prefix) to allow efficient cutting of both restriction endonucleases. -- Mike Speer

Andrew Kirk, undergraduate, Penn State iGEM 2010

When designing our project, we were thinking about using the violacein pigment, K274002, in our genetic circuit. This part is supposed to be just the coding sequence. Because the tube in the picture [http://2010.igem.org/Team:Penn_State/Project#Characterization_of_Old_BioBrick_parts on our website] only this part with no promoter added, there should be no expression of violacein. However, as can be seen below, the violacein is present. This could be caused by either an undocumented promoter within the part, or a non-insulated BioBrick vector with inefficient flanking transcriptional terminators.

Karina Arnesen, undergraduate, Alberta iGEM 2010

We also failed to transform K274002. We attempted to transform K274002 from both location in the 2011 registry shipment and the 2010 registry shipment.